What are BioMarin Pharmaceutical's price targets for the next 12 months?
14 brokers have issued 1-year price targets for BioMarin Pharmaceutical's stock. Their forecasts range from $88.00 to $152.00. On average, they expect BioMarin Pharmaceutical's stock price to reach $112.57 in the next twelve months. This suggests a possible upside of 30.9% from the stock's current price.
What is BioMarin Pharmaceutical's (bmrn) stock price potential upside?
On average, they expect BioMarin Pharmaceutical's stock price to reach $112.57 in the next twelve months. This suggests a possible upside of 30.9% from the stock's current price.
Does BioMarin Pharmaceutical stock pay a dividend?
BioMarin Pharmaceutical does not currently pay a dividend. BioMarin Pharmaceutical does not have a long track record of dividend growth. In the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought.
What does BioMarin Pharmaceutical do?
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases.
Is BioMarin a publicly traded company?
BioMarin Announces Public Offering of Common Stock. SAN RAFAEL, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of 7,500,000 shares of its common stock in an underwritten public offering.
Is BioMarin stock a buy?
BioMarin Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.79, and is based on 11 buy ratings, 3 hold ratings, and no sell ratings.
Who owns BioMarin?
Biomarin Pharmaceutical Inc (NASDAQ:BMRN) Institutional investors hold a majority ownership of BMRN through the 98.63% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry.
Is BioMarin a buy Zacks?
Zacks' proprietary data indicates that BioMarin Pharmaceutical Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the BMRN shares relative to the market in the next few months.
Is BioMarin a good company?
SAN RAFAEL, Calif., April 17, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has been ranked fourth on Forbes magazine's 2019 list of "America's Best Midsize Employers," increasing from 51st on last year's 2018 list.
Is BioMarin a biotech company?
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions.
What products do BioMarin make?
Our ProductsVOXZOGO™ (vosoritide)PALYNZIQ® (pegvaliase-pqpz) Injection.Brineura® (cerliponase alfa)Vimizim® (elosulfase alfa)Kuvan® (sapropterin dihydrochloride)Naglazyme® (galsulfase)Aldurazyme® (laronidase)
How many employees does BioMarin have?
Interactive chart of BioMarin Pharmaceutical (BMRN) annual worldwide employee count from 2010 to 2022. BioMarin Pharmaceutical total number of employees in 2021 was 3,045, a 0.46% decline from 2020. BioMarin Pharmaceutical total number of employees in 2020 was 3,059, a 1.93% increase from 2019.
Should I buy or sell BioMarin Pharmaceutical stock right now?
13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are cur...
What is BioMarin Pharmaceutical's stock price forecast for 2022?
13 Wall Street analysts have issued 12-month price targets for BioMarin Pharmaceutical's shares. Their forecasts range from $88.00 to $147.00. On a...
How has BioMarin Pharmaceutical's stock price performed in 2022?
BioMarin Pharmaceutical's stock was trading at $88.35 at the beginning of 2022. Since then, BMRN stock has decreased by 15.0% and is now trading at...
When is BioMarin Pharmaceutical's next earnings date?
BioMarin Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast...
How were BioMarin Pharmaceutical's earnings last quarter?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted its quarterly earnings data on Wednesday, April, 27th. The biotechnology company reported $0.31 e...
What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?
BioMarin Pharmaceutical updated its FY 2022 earnings guidance on Wednesday, March, 16th. The company provided earnings per share (EPS) guidance of...
Who are BioMarin Pharmaceutical's key executives?
BioMarin Pharmaceutical's management team includes the following people: Mr. Jean-Jacques Bienaime M.B.A. , MBA, Chairman & CEO (Age 69, Pay $3....
What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?
161 employees have rated BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé on Glassdoor.com . Jean-Jacques Bienaimé has an approval rating of 94%...
Who are some of BioMarin Pharmaceutical's key competitors?
Some companies that are related to BioMarin Pharmaceutical include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Rege...
About BioMarin Pharmaceutical
BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W.
Where is BioMarin Pharmaceuticals located?
14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 3 hold ratings and 11 buy ratings for the stock.
Where is BioMarin located?
Fiscal Q1 2021 ended 3/31/21. Reported on 4/29/21. BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe.
Does market cap include convertible securities?
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies.
Does BioMarin sell PKU?
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
Nasdaq Global Select
BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and.
Environmental, Social, and Governance Rating
The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Transparency is our policy. Learn how it impacts everything we do
The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
How we make money
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
How we use your personal data
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management.
How we approach editorial content
How we use your information depends on the product and service that you use and your relationship with us. We may use it to: